Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
23 hedge funds and large institutions have $9.91M invested in Trillium Therapeutics Inc. in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 11 closing their positions.
12% less funds holding
Funds holding: 26 → 23 (-3)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
75% less capital invested
Capital invested by funds: $40.3M → $9.91M (-$30.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$523K |
| 2 |
Morgan Stanley
New York
|
+$500K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$171K |
| 4 |
Jane Street
New York
|
+$74K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$69.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$4.07M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.9M |
| 3 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$809K |
| 4 |
Renaissance Technologies
New York
|
-$673K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$538K |
TRIL Hedge Fund Activity: Q4 2018 in Review
23 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2018, worth a combined $9.91M — down 75% from $40.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TRIL and 8 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $523K. The largest seller was AWM Investment Company, exiting entirely with an estimated $4.07M sold.
- 23 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2018, down from 26 in Q3 2018.
- Funds reported $9.91M of Trillium Therapeutics Inc. stock for Q4 2018, down 75% quarter-over-quarter.
- 8 funds opened new Trillium Therapeutics Inc. positions in Q4 2018 and 11 closed out, a net change of -3 holders.
- The largest Trillium Therapeutics Inc. buyer in Q4 2018 was Anson Funds Management, an estimated $523K added.
- The largest Trillium Therapeutics Inc. seller in Q4 2018 was AWM Investment Company, an estimated $4.07M sold.
Based on aggregated 13F filings for Q4 2018.